This trial is active, not recruiting.

Condition mrsa - methicillin resistant staphylococcus aureus infection
Treatment decolonization
Phase phase 4
Sponsor NorthShore University HealthSystem Research Institute
Start date October 2010
End date March 2013
Trial size 4200 participants
Trial identifier NCT01302210, AHRQ 1R18HSO19968-01


Our hypothesis for the DERAIL MRSA program is that one can safely remove the colonization risk from nearly all residents (patients) in a way that does not interfere with the desired life-style for persons in these facilities and thereby reduce the risk of infection and lower the cost of care by avoiding preventable disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Active surveillance testing for MRSA and decolonization of positive subjects
decolonization Mupirocin
5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
(No Intervention)
Usual standard of care

Primary Outcomes

To test the effectiveness of an admission testing and immediate decolonization of positive persons protocol for reducing MRSA colonization prevalence in long term care facilities (LTCF's)
time frame: 12 months and 24 months

Secondary Outcomes

To further develop an Infection Control Outreach Program designed to provide expert guidance on infectious disease prevention specific to LTCF's
time frame: 2 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - All patients in 18 LTCF nursing units randomly selected as intervention or control units Exclusion Criteria: - Patients that choose not to be included in the program

Additional Information

Official title Detection, Education, Research and Decolonization Without Isolation in Long-term Care to Control(DERAIL)MRSA
Principal investigator Lance R Peterson, MD
Description The primary endpoint will be measuring the reduction in MRSA colonization prevalence (rate) in the intervention arm as compared to the control arm. One secondary endpoint is to compare the rate of MRSA disease in the intervention and control arms. The other secondary endpoint is to determine the cost of MRSA screening and decolonization and compare it to the cost of MRSA disease treatment (both medication cost and the expense of any needed hospitalization for therapy of MRSA infection therapy) in the control arm. Achieving our primary goal of MRSA control will also demonstrate two secondary goals wthe investigators aim to achieve: one being that a scientific, planned approach to the issue of specific healthcare-associated infection in LTCFs can solve these problems and the other that a partnership between acute and long-term care is beneficial in dealing with patient safety and quality practices across the United Sates Healthcare continuum.
Trial information was received from ClinicalTrials.gov and was last updated in February 2011.
Information provided to ClinicalTrials.gov by NorthShore University HealthSystem Research Institute.